Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thymoglobulin + sirolimus + mycophenolate mofetil
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A multi-drug immunosuppressive regimen combining Thymoglobulin, sirolimus, and mycophenolate mofetil used primarily in solid organ transplantation for induction and maintenance of immunosuppression. Thymoglobulin is rabbit anti-thymocyte globulin, a polyclonal antibody preparation that depletes circulating T cells and modulates immune activation pathways. Sirolimus (rapamycin) is an mTOR inhibitor that blocks IL-2-driven T-cell proliferation and inhibits mTORC1-mediated cell-cycle progression. Mycophenolate mofetil is a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase to block de novo guanine nucleotide synthesis, selectively suppressing proliferation of T and B lymphocytes. Together, the combination provides complementary mechanisms: rapid lymphocyte depletion and immunomodulation (Thymoglobulin), signal transduction blockade of lymphocyte proliferation (sirolimus), and antiproliferative inhibition of nucleotide synthesis (mycophenolate), aiming to prevent acute rejection and support graft survival.
- Other names
- rATG + sirolimus + MMF
02
Targets
FKBP1AHLA-I/DR (HLA class I heavy chains and HLA-DR)IL2RA (Interleukin-2 receptor alpha subunit)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)LFA-1 (Integrin αLβ2)Mechanistic target of rapamycin complex 1CD2 (T-cell Surface Antigen CD2)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD8A (CD8 alpha/beta Coreceptor)HLA class I heavy chainHLA-DR (Human leukocyte antigen DR)ITGB2 (Complement receptor 4)
Beyond the preview
Go deeper on thymoglobulin + sirolimus + mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thymoglobulin + sirolimus + mycophenolate mofetil.